188 related articles for article (PubMed ID: 31732331)
1. Mechanistic target of rapamycin (mTOR) signaling in status epilepticus.
Crino PB
Epilepsy Behav; 2019 Dec; 101(Pt B):106550. PubMed ID: 31732331
[TBL] [Abstract][Full Text] [Related]
2. Early polytherapy for benzodiazepine-refractory status epilepticus.
Niquet J; Lumley L; Baldwin R; Rossetti F; Schultz M; de Araujo Furtado M; Suchomelova L; Naylor D; Franco-Estrada I; Wasterlain CG
Epilepsy Behav; 2019 Dec; 101(Pt B):106367. PubMed ID: 31636007
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of (immuno)proteasome subunits during epileptogenesis is attenuated by inhibition of the mammalian target of rapamycin pathway.
Broekaart DWM; van Scheppingen J; Geijtenbeek KW; Zuidberg MRJ; Anink JJ; Baayen JC; Mühlebner A; Aronica E; Gorter JA; van Vliet EA
Epilepsia; 2017 Aug; 58(8):1462-1472. PubMed ID: 28643873
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage.
Brewster AL; Lugo JN; Patil VV; Lee WL; Qian Y; Vanegas F; Anderson AE
PLoS One; 2013; 8(3):e57808. PubMed ID: 23536771
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin reveals an mTOR-independent repression of Kv1.1 expression during epileptogenesis.
Sosanya NM; Brager DH; Wolfe S; Niere F; Raab-Graham KF
Neurobiol Dis; 2015 Jan; 73():96-105. PubMed ID: 25270294
[TBL] [Abstract][Full Text] [Related]
6. Spatiotemporal characterization of mTOR kinase activity following kainic acid induced status epilepticus and analysis of rat brain response to chronic rapamycin treatment.
Macias M; Blazejczyk M; Kazmierska P; Caban B; Skalecka A; Tarkowski B; Rodo A; Konopacki J; Jaworski J
PLoS One; 2013; 8(5):e64455. PubMed ID: 23724051
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
8. The seventh London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures.
Shorvon S; Trinka E; Walker M
Epilepsy Behav; 2019 Dec; 101(Pt B):106532. PubMed ID: 31685383
[TBL] [Abstract][Full Text] [Related]
9. Effects of rapamycin and curcumin on inflammation and oxidative stress in vitro and in vivo - in search of potential anti-epileptogenic strategies for temporal lobe epilepsy.
Drion CM; van Scheppingen J; Arena A; Geijtenbeek KW; Kooijman L; van Vliet EA; Aronica E; Gorter JA
J Neuroinflammation; 2018 Jul; 15(1):212. PubMed ID: 30037344
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation.
van Vliet EA; Forte G; Holtman L; den Burger JC; Sinjewel A; de Vries HE; Aronica E; Gorter JA
Epilepsia; 2012 Jul; 53(7):1254-63. PubMed ID: 22612226
[TBL] [Abstract][Full Text] [Related]
11. Autophagy and autophagy signaling in Epilepsy: possible role of autophagy activator.
Ali NH; Al-Kuraishy HM; Al-Gareeb AI; Alnaaim SA; Alexiou A; Papadakis M; Saad HM; Batiha GE
Mol Med; 2023 Oct; 29(1):142. PubMed ID: 37880579
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor receptor-3 regulates astroglial glutamate transporter-1 expression via mTOR activation in reactive astrocytes following pilocarpine-induced status epilepticus.
Jeong KH; Cho KO; Lee MY; Kim SY; Kim WJ
Glia; 2021 Feb; 69(2):296-309. PubMed ID: 32835451
[TBL] [Abstract][Full Text] [Related]
13. Regulation of cell death and epileptogenesis by the mammalian target of rapamycin (mTOR): a double-edged sword?
Zeng LH; McDaniel S; Rensing NR; Wong M
Cell Cycle; 2010 Jun; 9(12):2281-5. PubMed ID: 20603607
[TBL] [Abstract][Full Text] [Related]
14. Impact of rapamycin on status epilepticus induced hippocampal pathology and weight gain.
Hester MS; Hosford BE; Santos VR; Singh SP; Rolle IJ; LaSarge CL; Liska JP; Garcia-Cairasco N; Danzer SC
Exp Neurol; 2016 Jun; 280():1-12. PubMed ID: 26995324
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mTOR Pathway by Rapamycin Decreases P-glycoprotein Expression and Spontaneous Seizures in Pharmacoresistant Epilepsy.
Chi X; Huang C; Li R; Wang W; Wu M; Li J; Zhou D
J Mol Neurosci; 2017 Apr; 61(4):553-562. PubMed ID: 28229367
[TBL] [Abstract][Full Text] [Related]
16. Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target.
Galanopoulou AS; Gorter JA; Cepeda C
Epilepsia; 2012 Jul; 53(7):1119-30. PubMed ID: 22578218
[TBL] [Abstract][Full Text] [Related]
17. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis.
Citraro R; Leo A; Constanti A; Russo E; De Sarro G
Pharmacol Res; 2016 May; 107():333-343. PubMed ID: 27049136
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor-γ agonist inhibits the mammalian target of rapamycin signaling pathway and has a protective effect in a rat model of status epilepticus.
San YZ; Liu Y; Zhang Y; Shi PP; Zhu YL
Mol Med Rep; 2015 Aug; 12(2):1877-83. PubMed ID: 25891824
[TBL] [Abstract][Full Text] [Related]
19. Neurostimulation in the treatment of refractory and super-refractory status epilepticus.
Trinka E; Brigo F
Epilepsy Behav; 2019 Dec; 101(Pt B):106551. PubMed ID: 31676239
[TBL] [Abstract][Full Text] [Related]
20. Targeting of microRNA-21-5p protects against seizure damage in a kainic acid-induced status epilepticus model via PTEN-mTOR.
Tang C; Gu Y; Wang H; Wu H; Wang Y; Meng Y; Han Z; Gu Y; Ma W; Jiang Z; Song Y; Na M; Lu D; Lin Z
Epilepsy Res; 2018 Aug; 144():34-42. PubMed ID: 29751355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
